Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 313 to 315 of 315 entries
Sorted by: Best Match Show Resources per page
Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.

Focus (American Psychiatric Publishing)

Forester BP, Parikh SV, Weisenbach S, Ajilore O, Vahia I, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Shelton RC, Macaluso M, Li J, Traxler P, Logan J, Brown L, Dechairo B, Greden JF.
PMID: 34483773
Focus (Am Psychiatr Publ). 2021 Jan;19(1):76-85. doi: 10.1176/appi.focus.19107. Epub 2021 Jan 25.

(Reprinted with permission from

Cite
Forester BP, Parikh SV, Weisenbach S, et al. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Focus (Am Psychiatr Publ). 2021;19(1):76-85doi: 10.1176/appi.focus.19107.
Forester, B. P., Parikh, S. V., Weisenbach, S., Ajilore, O., Vahia, I., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Shelton, R. C., Macaluso, M., Li, J., Traxler, P., Logan, J., Brown, L., Dechairo, B., & Greden, J. F. (2021). Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Focus (American Psychiatric Publishing), 19(1), 76-85. https://doi.org/10.1176/appi.focus.19107
Forester, Brent P, et al. "Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression." Focus (American Psychiatric Publishing) vol. 19,1 (2021): 76-85. doi: https://doi.org/10.1176/appi.focus.19107
Forester BP, Parikh SV, Weisenbach S, Ajilore O, Vahia I, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Shelton RC, Macaluso M, Li J, Traxler P, Logan J, Brown L, Dechairo B, Greden JF. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Focus (Am Psychiatr Publ). 2021 Jan;19(1):76-85. doi: 10.1176/appi.focus.19107. Epub 2021 Jan 25. PMID: 34483773; PMCID: PMC8412149.
Copy Download .nbib Format: NLM
Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

The International journal on drug policy

Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Nicholas T, Weiss R, Rodgers C, Cook J, Degenhardt L.
PMID: 34736130
Int J Drug Policy. 2021 Nov 01;100:103492. doi: 10.1016/j.drugpo.2021.103492. Epub 2021 Nov 01.

BACKGROUND: Opioid agonist treatment (OAT) is an effective intervention for opioid dependence. Extended-release buprenorphine injections (BUP-XR) may have additional potential benefits over sublingual buprenorphine. This single-arm trial evaluated outcomes among people receiving 48 weeks of BUP-XR in diverse community...

Cite
Farrell M, Shahbazi J, Byrne M, et al. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Int J Drug Policy. 2021;100:103492doi: 10.1016/j.drugpo.2021.103492.
Farrell, M., Shahbazi, J., Byrne, M., Grebely, J., Lintzeris, N., Chambers, M., Larance, B., Ali, R., Nielsen, S., Dunlop, A., Dore, G. J., McDonough, M., Montebello, M., Nicholas, T., Weiss, R., Rodgers, C., Cook, J., Degenhardt, L. (2021). Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. The International journal on drug policy, 100103492. https://doi.org/10.1016/j.drugpo.2021.103492
Farrell, Michael, et al. "Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence." The International journal on drug policy vol. 100 (2021): 103492. doi: https://doi.org/10.1016/j.drugpo.2021.103492
Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Nicholas T, Weiss R, Rodgers C, Cook J, Degenhardt L. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Int J Drug Policy. 2021 Nov 01;100:103492. doi: 10.1016/j.drugpo.2021.103492. Epub 2021 Nov 01. PMID: 34736130.
Copy Download .nbib Format: NLM
Enhancing Hispanic participation in mental health clinical research: development of a Spanish-speaking depression research site.

Larson J, Aponte-Rivera V, Dunlop BW, Ramirez C, Kelley ME, Schneider R, Blastos B, Mercado F, Mayberg H, Craighead WE.
UIID-AD: 2942
2014;31:258-67. doi: 10.1002/da.22153.

BACKGROUND: Hispanics, particularly those with limited English proficiency, are underrepresented in psychiatric clinical research studies. We developed a bilingual and bicultural research clinic dedicated to the recruitment and treatment of Spanish-speaking subjects in the Predictors of Remission in Depression...

Cite
Larson J, Aponte-Rivera V, Dunlop BW, et al. Enhancing Hispanic participation in mental health clinical research: development of a Spanish-speaking depression research site. 2014;31:258-67doi: 10.1002/da.22153.
Larson, J., Aponte-Rivera, V., Dunlop, B. W., Ramirez, C., Kelley, M. E., Schneider, R., Blastos, B., Mercado, F., Mayberg, H., & Craighead, W. E. (2014). Enhancing Hispanic participation in mental health clinical research: development of a Spanish-speaking depression research site. 31258-67. https://doi.org/10.1002/da.22153
Larson, J, et al. "Enhancing Hispanic participation in mental health clinical research: development of a Spanish-speaking depression research site." vol. 31 (2014): 258-67. doi: https://doi.org/10.1002/da.22153
Larson J, Aponte-Rivera V, Dunlop BW, Ramirez C, Kelley ME, Schneider R, Blastos B, Mercado F, Mayberg H, Craighead WE. Enhancing Hispanic participation in mental health clinical research: development of a Spanish-speaking depression research site. 2014;31:258-67. doi: 10.1002/da.22153. UIID-AD: 2942.
Copy Download .nbib Format: NLM
Showing 313 to 315 of 315 entries